Filiz Kaya

Filiz Kaya

Auto-generated profile, based on publicly available information

Filiz Kaya

Genetic Engineering and Biotechnology Institute, Marmara Research Center, TÜBİTAK, Kocaeli Turkey

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 June 2020 in TURKISH JOURNAL OF BIOLOGY
Verified
Journal Article
Open access
BBBertan Koray Balcioğlu
Bertan Koray Balcioğlu
MÖMelis Denizci Öncü
Melis Denizci Öncü
HÖHasan Ümit Öztürk
Hasan Ümit Öztürk
FYFatıma YÜCEL
Fatıma YÜCEL
FKFiliz Kaya
Filiz Kaya
ABAylin Özdemir Bahadir
Aylin Özdemir Bahadir
In December 2019 a novel coronavirus was detected in Wuhan City of Hubei Province-China. Owing to a high rate of transmission from human to human, the new virus called SARS-CoV-2 differed from others by its unexpectedly rapid spread. The World Health Organization (WHO) described the most recent coronavirus epidemic as a global pandemic in March 2020. The virus spread triggered a health crisis (the COVID-19 disease) within three months, with socioeconomic implications. No approved targeted-therapies are available for COVID-19, yet. However, it is foreseen that antibody-based treatments may provide an immediate cure for patients. Current neutralizing antibody development studies primarily target the S protein among the structural elements of SARS-CoV-2, which mediates the cell entry of the virus through the angiotensin converting enzyme 2 (ACE2) receptor of host cells. This review aims to provide some of the neutralizing antibody development strategies for SARS-CoV-2 and in vitro and in vivo neutralization assays.